Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 21;30(6):1696–1710. doi: 10.1038/s41591-024-02953-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 4 — (a) Longitudinal comparison of the factor value of Integrative ACS Ischemia between patients with sterile ACS with and without pre-medication. ASA, ß-Blocker, ACE/AT1-inhibitor, Statin. The dataset was analyzed using the Mixed-effects analysis with correction for multiple comparisons by Šidák test. *p≤0.05. Mean values with +/- SEM are shown. (b) Integrative ACS Ischemia (Factor 2). Comparison of the factor values of each timepoint of sterile ACS (TP1-4M) and non-CCS (TP0M) with CCS (TP0M) patients. Only patients without pre-medication (upper part) of: ASA, ß-Blocker, ACE/AT1-inhibitor, Statin. Only patients with pre-medication (lower part) of: ASA, ß-Blocker, ACE/AT1-inhibitor, Statin. Parametric distributed data were analyzed using the Ordinary One-Way ANOVA with correction for multiple comparisons by Dunnett’s test; non-parametric distributed data were analyzed using the Kruskal-Wallis test with correction for multiple comparisons by Dunn’s test. *p≤0.05, **p≤0.01, ***p≤0.001. Mean values with +/- SEM are shown. (c) Comparison of the factor value (Integrative ACS Ischemia, Factor 2) in patients without ACS (pooled non-CCS and CCS) between with and without respective pre-medication: ASA, ß-Blocker, ACE/AT1-inhibitor, Statin. The parametric dataset was analyzed using an unpaired t-test (two-sided). *p≤0.05. Mean values with +/- SEM are shown. (d) Integrative ACS Ischemia (Factor 2). Comparison of the factor values of TP1-3M with TP4M of patients with sterile ACS. Only patients without pre-medication (upper part) of: ASA, ß-Blocker, ACE/AT1-inhibitor, Statin. Only patients with pre-medication (lower part) of: ASA, ß-Blocker, ACE/AT1-inhibitor, Statin. Parametric distributed data were analyzed using the Ordinary One-Way ANOVA with correction for multiple comparisons by Dunnett’s test; non-parametric distributed data were analyzed using the Kruskal-Wallis test with correction for multiple comparisons by Dunn’s test. *p≤0.05, **p≤0.01, ***p≤0.001. Mean values with +/- SEM are shown. (a) – (d) Exact p-values (Supplementary Table 13) and n-numbers (Supplementary Table 14) were summarized in the supplementary tables.